MarketPulse

thalassemia

2 articles
The Motley FoolThe Motley Fool··Eric Volkman

Agios Pharmaceuticals Surges 13% on Beat Earnings, Expanding Mitapivat Market

Agios Pharmaceuticals surged 13% on strong Q1 earnings, with mitapivat revenue jumping 138% to $20.7M. Company plans supplemental FDA application for sickle cell disease expansion.
AGIOFDA approvalsickle cell disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Agios Pharmaceuticals Eyes Accelerated FDA Approval Path for Mitapivat in Sickle Cell

Agios Pharmaceuticals to report Q1 2026 results April 29 amid FDA accelerated approval pursuit for sickle cell mitapivat and UAE thalassemia approval.
AGIOrare diseasesFDA